HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 476 participants.

Also called NCT04556851

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 476 participants (enrolled count) (from the registry)
Sponsor
Sichuan Haisco Pharmaceutical Group Co., Ltd (from the registry)
Registry
  • NCT NCT04556851
Other papers using this trial's data
  • Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, phase 3 trial Diabetes, obesity & metabolism, 2025-01 DOI, PubMed 39434431, PMC11618291 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04556851. Randomized; double masking; primary purpose treatment. Start 2020-09-29 (actual); primary completion 2022-01-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
HSK7653 10 mg Q2W
Intervention (Drug)
HSK7653 25 mg Q2W
Intervention (Drug)
Placebo
Lead sponsor
Sichuan Haisco Pharmaceutical Group Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct04556851
Content hash
b67e678e9455e5c829e0450facba144f671ac9ef06b0283c07a98aa244edd3e6